Onkologie-VirtuOS

Roche Onkologie VirtuOS

Berlin, SHERATON BERLIN GRAND HOTEL ESPLANADE, 05.06-07.06.2017

Agenda für Montag, 05.06.2017

Uhrzeit Programm
13:00 – 14:40 Uhr

Virtual ASCO

  • Gastrointestinal Cancer
    • Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. (Salah-Eddin Al-Batran – 4004)
    • Breaking Barriers in the Treatment of Gastroesophageal Cancers (Yoon-Koo Kang – 4003, 4004, 4014)
    • Horizontal and Vertical Shifts in the Treatment of Hepatocellular Carcinoma (Robin Kate Kelley – 4000, 4001, 4002)
    • Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. (Qian Shi – LBA1)
  • Next Generation Sequencing
    • Discussion - Translating Tumor Sequencing Into Clinical Decision-Making: The Record to Date (Bryan P. Schneider)
14:40 – 15:10 Uhr Pause
15:10 – 16:00 Uhr

Diskussion mit Experten aus Deutschland (Live-Satellitenschaltung nach Chicago)

  • Schwerpunkt Gastrointestinale Tumore (Prof. Stintzing, München und Prof. Al-Batran, Frankfurt a.M)
  • Schwerpunkt Translationale Medizin (Prof. Krämer, Heidelberg und Prof. Weichert, München)
16:00 – 16:45 Uhr

Virtual ASCO

  • Prostate Cancer
    • Highlights of the Day I: Prostate Cancer (Charles J. Ryan)
    • LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Karim Fizazi – LBA3)
16:45 – 16:55 Uhr Pause
16:55 – 18:15 Uhr

Virtual ASCO

  • Immunotherapy in Lung Cancer
    • Role of Checkpoint Inhibitors in First Line Therapy and How to Sequence Immunotherapy (Edward B. Garon)
    • Are All Immunotherapy Drugs the Same or Is One the Best? (Melissa Lynne Johnson)
    • What Is the Role of PD-L1 Biomarker Testing in Clinical Practice? (Aaron Scott Mansfield)
  • Hematologic Malignancies
    • Highlights of the Day I: Lymphoma and Chronic Lymphocytic Leukemia (Gilles A. Salles)
18.15 – 18.30 Uhr Abschlussdiskussion

Agenda für Dienstag, den 06.06.2017

Uhrzeit Programm
8:30 – 10:30 Uhr

Virtual ASCO

  • Hematologic Malignancies
    • Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status. (Katja C. Weisel – 8006)
    • Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study. (Jeff Porter Sharman – 7504)
    • Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. (Michael Pfreundschuh – 7506)
    • First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. (Ian Flinn – 7500)
  • Genitourinary (Nonprostate) Cancer
    • IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). (Michael B. Atkins – 4505)
    • First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. (Toni K. Choueiri – 4504)
    • Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). (Dean F. Bajorin – 4501)
10:30 – 11:00 Uhr Pause
11:00 – 12:15 Uhr

Virtual ASCO

  • Lung Cancer
    • ADC to HER2 Rescue? (Leena Gandhi – 8509, 8510)
    • More to MET Than Meets the Eye. (Patrick C. Ma – 8511, 8512)
  • Melanoma/Skin Cancers
    • Highlights of the Day II: Melanoma/Skin Cancers. (Tara C. Gangadhar)
12:15 – 13:15 Uhr Mittagspause
13:15 – 14:40 Uhr

Virtual ASCO

  • Breast Cancer
    • MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy (George W. Sledge – 1000)
    • OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). (Mark E. Robson – LBA4)
    • Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Nadia Harbeck – 504)
    • APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). (Gunter Von Minckwitz – LBA500)
  • Gynecologic Cancer
    • The Evolving Surgical Paradigm (Ritu Salani – 5500, 5501, 5502)
14:40 – 15:10 Uhr

Pause

15:10 – 17:10 Uhr

Diskussion mit Experten aus Deutschland (Live-Satellitenschaltung nach Chicago)

  • Schwerpunkt Lungenkrebs (PD Dr. Heigener, Großhansdorf und Dr. Dickgreber, Rheine)
  • Schwerpunkt Hämatologie (Prof. Glaß, Berlin und Prof. Schmitt, Berlin)
  • Schwerpunkt Urogenitale Tumore (Prof. Grünwald, Hannover)
  • Schwerpunkt Brustkrebs (Prof. Schneeweiss, Heidelberg und Prof. Müller, Hamburg)
17:10 – 17:20 Uhr

Pause

17:20 – 18:15 Uhr

Virtual ASCO

  • Gastrointestinal Tumors
    • Highlights of the Day Session II (Tanios S. Bekaii-Saab)
    • Is three months a good idea?. (Jeffrey A. Meyerhardt – 3500, 3501, 3502)
    • Going Nuts About Early-Stage Colon Cancer. (Steven J. Cohen – 3514, 3515, 3516, 3617)
18:15 – 18.30 Uhr Abschlussdiskussion

Agenda für Mittwoch, den 07.06.2017

Uhrzeit Programm
8:30 – 10:30 Uhr

Virtual ASCO

  • Highlights of the Day II/III
    • Central Nervous System Tumors. (David M. Peereboom)
    • Head and Neck Cancer. (Nabil F. Saba)
    • Genitourinary Cancers (Non-prostate). (Petros Grivas)
  • Breast Cancer
    • Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. (Sylvia Adams – 1008)
    • Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE. (Edith A. Perez – 1003)
10:30 – 11:00 Uhr Pause
11:00 – 12:00 Uhr

Virtual ASCO

  • Lung Cancer—Non-Small Cell Metastatic
    • Efficacy and Safety Results from AvaALL: An Open-Label, Randomized Phase III Trial of Standard of Care (SOC) With or Without Continuous Bevacizumab (Bev) Treatment Beyond Progression (PD) in Patients (pts) with Advanced Non-Small Cell Lung cancer (NSCLC) Progressing After First-Line Bev and Chemotherapy (chemo) (Jaafar Bennouna – 9004)
    • Alectinib Versus Crizotinib in Treatment-Naive Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC): Primary Results of the Global Phase III ALEX Study. (Alice Tsang Shaw – LBA9008)
    • Long-Term Survival With Immunotherapy: Stretching the Tail. (Solange Peters – 9000, 9001)
12:00 – 13:00 Uhr Mittagspause
13:00 – 14:00 Uhr

Virtual ASCO

  • Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
    • New Approaches in Small Cell Lung Cancer: Hope or Hype? (Edward B. Garon – 8503, 8504, 8505)
    • Teaching "Old" Drugs New Tricks. (Anne S. Tsao – 8506, LBA8507, 8508)
14:00 – 14:20 Uhr Pause
14:20 – 15:55 Uhr

Virtual ASCO

  • Hematologic Malignancies
    • Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial. (Jorge E. Cortes – 7002)
    • Highlights of the Day Session II: Plasma Cell Dyscrasia. (S. Vincent Rajkumar)
  • Gastrointestinal Cancer
    • Making Sense of Consensus Molecular Subtypes. (Wells A. Messersmith)
    • PERSIST-5: Five Year Extended Treatment with Adjuvant Imatinib for patients with Intermediate/High Risk Primary Gastrointestinal Stromal Tumor (GIST). (Chandrajit P. Raut - 11009)
    • Translating Biomarkers Into Clinical Practice. (Chloe Evelyn Atreya)
15:55 – 16:00 Uhr Abschlussdiskussion und Verabschiedung